EUVIMEDEUVIMED entdecken
Open Access

A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform

Yingying Jiang iD, Mrinmoy Sanyal iD, Noor A Hussein, Ani Baghdasaryan iD, Mengzhen Zhang, Feifei Wang iD, Fuqiang Ren, Jiachen Li iD, Guanzhou Zhu iD, Yifan Meng iD, Julia Zofia Adamska iD, Elizabeth Mellins iD und 1 weitere

Science Advances · 07.02.2025 · 11 (6)

DOI: 10.1126/sciadv.adp5539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 07.02.2025. Verfasst von Yingying Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Bio-X, Stanford University, Stanford, CA, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, SARS-CoV-2, Nanoparticles, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic caused a global health crisis that resulted in millions of deaths. Effective vaccines have played central roles in curtailing the pandemic. Here, we developed a down-converting near-infrared IIb (NIR-IIb; 1500 to 1700 nanometers) luminescent, pure NaErF 4 @NaYF 4 rare-earth nanoparticle (pEr) as vaccine carriers. The pEr nanoparticles were coated with three layers of cross-linked biocompatible polymers (pEr-P 3 ; ~55 nanometers) and conjugated to the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Upon subcutaneous injection of the pEr-P 3 -RBD nanovaccine in mice, in vivo NIR-IIb imaging revealed active vaccine trafficking and migration to lymph nodes through lymphatic vessels. Two doses of the adjuvant-free vaccine elicited long-lasting (>7 months) high titers of serum viral neutralization antibody and anti-RBD immunoglobulin G, along with robust RBD-specific germinal center B cells and T follicular helper cells. We devised in vivo NIR-II molecular imaging of RBD-specific cells in lymph nodes, opening noninvasive assessments of vaccine-elicited immune responses longitudinally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesSARS-CoV-2NanoparticlesCOVID-19AnimalsSpike Glycoprotein, CoronavirusMiceAntibodies, ViralAntibodies, NeutralizingHumansFemaleLymph NodesInfrared Rays

Substanzen

COVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Chemistry and Bio-X, Stanford University, Stanford, CA, USA.
  • Department of Chemistry, The University of Hong Kong, Pokfulam, Hong Kong SAR.
  • Materials Innovation Institute for Life Sciences and Energy (MILES), HKU-SIRI, Shenzhen, P. R. China.
  • Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Department of Biochemistry, School of Medicine, Stanford University, Stanford, CA, USA.
  • Department of Pediatrics, Stanford University, Stanford, CA, USA.

ORCID-Profile: Yingying Jiang, Mrinmoy Sanyal, Ani Baghdasaryan, Feifei Wang, Jiachen Li, Guanzhou Zhu, Yifan Meng, Julia Zofia Adamska, Elizabeth Mellins, Hongjie Dai

Förderung

  • NINDS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Jiang, Y., Sanyal, M., Hussein, N. A., Baghdasaryan, A., Zhang, M., Wang, F., Ren, F., Li, J., Zhu, G., Meng, Y., Adamska, J. Z., Mellins, E., & Dai, H. (2025). A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform. Science Advances, 11(6). https://doi.org/10.1126/sciadv.adp5539

Vancouver

Jiang Y, Sanyal M, Hussein NA, Baghdasaryan A, Zhang M, Wang F, et al. A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform. Science Advances. 2025;11(6). doi:10.1126/sciadv.adp5539

BibTeX
@article{Jiang2025,
  author = {Jiang, Yingying and Sanyal, Mrinmoy and Hussein, Noor A and Baghdasaryan, Ani and Zhang, Mengzhen and Wang, Feifei and Ren, Fuqiang and Li, Jiachen and Zhu, Guanzhou and Meng, Yifan and Adamska, Julia Zofia and Mellins, Elizabeth and Dai, Hongjie},
  title = {A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {6},
  doi = {10.1126/sciadv.adp5539}
}
Kostenlos starten →